Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who had hematopoietic stem cell transplantation (HSCT) for beta-thalassemia major
hematopoietic stem cell transplantation (HSCT) was performed minimum 6 months and maximum 2 years ago
The washout period after the immunosuppressive therapy should be at least 3 months.
Signifacant IOL should be present including:
A. Serum ferritin \>1000 μg/L or B. cardiac MRI \<20 ms or C. liver iron concentration ≥ 5 mg/g dry weight measured by R2\* MRI
You may not be if
Patients who had any contraindication for treatment with deferasirox according to the prescribing information
•Patients who depended on transfusion
Patients with clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias)
Patients who were experiencing severe complication of HSCT e.g. acute Graft-versus host disease (GVHD)
Significant proteinuria / Increase in serum creatinine